CSIMarket Company Name, Ticker, Suppliers, else..
 
Ladrx Corporation  (LADX)
Other Ticker:  
 
 
Price: $1.5300 $-0.14 -8.383%
Day's High: $1.53 Week Perf: -19.05 %
Day's Low: $ 1.53 30 Day Perf: -30.45 %
Volume (M): 0 52 Wk High: $ 3.50
Volume (M$): $ 0 52 Wk Avg: $2.07
Open: $1.53 52 Wk Low: $0.50



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 1
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -3
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) 0

Ladrx Corporation
Ladrx Corporation is a technology company that primarily focuses on the development and manufacturing of electronic devices and software systems. The company is known for producing innovative products in various industries, including telecommunications, consumer electronics, and automotive sectors.

Ladrx Corporation has a strong emphasis on research and development, constantly striving to create cutting-edge technologies that can improve the lives of its consumers. The company invests heavily in exploring new ideas and harnessing emerging technologies to stay ahead of the competition.

With a global presence, Ladrx Corporation has a diverse portfolio of products ranging from smartphones and tablets to smart home appliances and autonomous driving systems. The company places great importance on quality control, ensuring that its products are reliable, efficient, and meet the high standards expected by its customers.

Additionally, Ladrx Corporation is committed to sustainability and environmental conservation. The company incorporates eco-friendly practices and materials in its manufacturing processes and actively supports initiatives aimed at reducing carbon emissions.

Overall, Ladrx Corporation is a forward-thinking and technologically advanced company that strives to drive innovation and deliver superior products to its customers across various industries.


   Company Address: 11726 San Vicente Blvd. Los Angeles 90049 CA
   Company Phone Number: 826-5648   Stock Exchange / Ticker: LADX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN   -0.36%    
BIIB   -1.84%    
CHRS        12.48% 
EXEL   -0.16%    
GILD   -4.61%    
HALO        3.51% 
• View Complete Report
   



Business Update

Navigating New Horizons LadRx Corporation?s Strategic Push for Aldoxorubicin Under the FDA?s 505(b)(2) Pathway

Published Thu, Dec 12 2024 4:26 AM UTC

In a notable development within the realm of biopharmaceutical innovation, LadRx Corporation (OTCQB: LADX) a company dedicated to pioneering life-saving therapeutics for cancer has announced its strategic decision to resurrect the process for marketing approval of aldructorubicin, harnessing the provisions of the FDA?s Section 505(b)(2) pathway. This regulatory route is part...
Business Update

LadRx and ImmunityBio Conclude Strategic Termination of Aldoxorubicin Licensing Agreement

Published Tue, Jun 4 2024 1:38 AM UTC

LadRx and ImmunityBio Agree to Mutual Termination of Aldoxorubicin LicenseLadRx Corporation (OTCQB: LADX), a pioneering entity in the biopharmaceutical sector, specializing in life-saving cancer therapeutics, has announced a mutual agreement to terminate the aldoxorubicin license with NantCell, Inc. and its parent company, ImmunityBio, Inc.This pivotal development marks the...
Ladrx Corporation

Ladrx Corporation Turns Operating Shortfall into Progress with $1.080039 Million Improvement

As the earnings cycle for the fiscal period of January to March 2024 unfolds, companies across various industries are sharing their financial results. In particular, the Biotechnology & Pharmaceuticals sector has been in the spotlight, with many entities revealing their performance. One such company is LADX, which recently reported an operating shortfall of $-0.831897 million for the quarter ending on March 31, 2024.
While this figure may seem concerning at first glance, it is actually a positive development and deviates from the usual benchmarks. LADX has managed to significantly improve its operating shortfall compared to the same period last year, which stood at $-1.080039 million. This improvement has instilled confidence in numerous analysts regarding the company's prospects.
Ladrx Corporation

Expenses Mounting as Ladrx Corporation Reports Operating Shortfall in Q4 2023

Ladrx Corporation, a prominent player in the Biotechnology & Pharmaceuticals sector, has recently released its fourth-quarter earnings report for the year 2023. As Wall Street journalists, we are delving into the financial results to provide our readers with an in-depth analysis of the company's performance.
One crucial aspect to note is the operating shortfall of $-0.882108 million reported by Ladrx Corporation. The LADX has not cited any revenue for the October to December reporting period, leaving investors eager for new revenue streams to emerge. Despite this lack of revenue, investors seem more focused on the company's future potential rather than its current organizational and operational excellence.
Ladrx Corporation

Ladrx Corporation's Fiscal Report Reveals Operating Shortfall of $-0.840313 Million in Biotechnology & Pharmaceuticals Sector for September 2023

The stock market is an ever-evolving landscape, filled with opportunities for both investors and corporations alike. In the Biotechnology & Pharmaceuticals sector, some companies often go unnoticed, but they are now emerging with promising earnings. One such corporation is Ladrx Corporation, which recently reported a decrease in its operating shortfall for the third quarter of 2023.
In comparison to the third quarter of 2022, Ladrx Corporation's operating shortfall has significantly improved. Last year, the company experienced an operating shortfall of $-1.167527 million. However, this year, the shortfall has decreased to $-0.840313 million. These numbers serve as crucial signals for the state of Ladrx Corporation, indicating a positive trend in the company's financial performance.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com